-
Keep Eyes on: Synthetic Biologics Inc. (NYSEMKT:SYN), National Bank of Greece (NYSE:NBG), Pattern Energy. (NASDAQ:PEGI), Harmony Gold Mining (NYSE:HMY), Freeport-McMoRan (NYSE:FCX)
Synthetic Biologics, Inc. (NYSE: SYN) announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company’s investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. On Tuesday shares…
-
Healthcare Volatile Stocks: Anthera Pharmaceuticals (NASDAQ:ANTH), Unilife Corporation (NASDAQ:UNIS), Biocept (NASDAQ:BIOC), Synthetic Biologics Inc. (NYSEMKT:SYN), Molina Healthcare (NYSE:MOH)
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. An independent statistician conducted the interim futility analysis for the CHABLIS-SC1 study, evaluating the SRI-6 response at the…
-
Hot Watch List: Synthetic Biologics Inc. (NYSEMKT:SYN), Celgene Corporation (NASDAQ:CELG), The Boeing Company (NYSE:BA), Trina Solar Limited (NYSE:TSL), Avon Products Inc. (NYSE:AVP)
Shares of Synthetic Biologics (NYSEMKT:SYN) were the recipient of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 745,830 shares, a drop of 27.4% from the December 15th total of 1,027,039 shares. On Monday shares of Synthetic Biologics Inc. (NYSEMKT:SYN) closed at $1.74. Celgene…
-
Stocks Swings: Synthetic Biologics Inc. (NYSEMKT:SYN), Intel Corporation (NASDAQ:INTC), Merck & Co. Inc. (NYSE:MRK), Response Genetics, Inc (NASDAQ:RGDX), Interactive Intelligence Group (NASDAQ:ININ)
Synthetic Biologics Inc. (NYSEMKT:SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that enrollment has initiated and the first patient was dosed in a phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated…
-
Why Investors Are Watching: Synthetic Biologics (NYSEMKT:SYN), SandRidge Mississippian Trust I (NYSE:SDT), InterOil Corporation (NYSE:IOC), Fate Therapeutics (NASDAQ:FATE), Tootsie Roll Industries (NYSE:TR)
Synthetic Biologics Inc. (NYSEMKT: SYN) announced that enrollment has initiated and the first patient was dosed in a phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhoea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. Synthetic Biologics Inc.…
-
Big Moves in Focus: Statoil ASA (NYSE:STO), Amgen Inc. (NASDAQ:AMGN), Spirit Realty Capital (NYSE:SRC), Synthetic Biologics (NYSEMKT: SYN), Willis Group (NYSE:WSH)
On 19 December Statoil ASA (NYSE:STO) said that it has awarded a major oilfield services contract for its Mariner development in the North Sea. Statoil ASA (NYSE:STO) in last trading activity fell -1.08% to close at $17.42. Company weekly performance is -3.33% while its quarterly performance stands at -32.97%. Statoil ASA (NYSE:STO) is -44.20% away…
-
Stocks to Watch: BP p.l.c. (NYSE:BP), Synthetic Biologics Inc. (NYSEMKT:SYN), BankUnited (NYSE:BKU), Healthcare Realty Trust Incorporated (NYSE:HR), Audience (NASDAQ:ADNC)
BP p.l.c. (NYSE:BP) is asking the federal appeals court in New Orleans to kick out the administrator of damage settlement claims from its 2010 oil spill, said on Dec, 24. BP p.l.c. (NYSE:BP) in last trading activity moved up 0.13% to close at $39.03. Company weekly performance is -0.94% while its quarterly performance stands at…
-
Moving Stocks: Synthetic Biologics Inc. (NYSEMKT:SYN), Theravance Biopharma (NASDAQ:TBPH), Wyndham Worldwide Corporation (NYSE:WYN), Superior Energy Services (NYSE:SPN), FirstService Corporation (NASDAQ:FSRV)
Synthetic Biologics, Inc. (NYSEMKT:SYN) announced positive topline safety and tolerability results from a Phase 1a clinical trial of SYN-004, the Company’s investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. Synthetic Biologics Inc. (NYSEMKT:SYN) in last trading…
-
Stocks on the move: LinkedIn Corporation (NYSE:LNKD), Intel Corporation (NASDAQ:INTC), Synthetic Biologics Inc. (NYSEMKT:SYN), Vision-Sciences Inc. (NASDAQ:VSCI), CollabRx (NASDAQ:CLRX)
LinkedIn Corporation (NYSE:LNKD) CFO Steven J. Sordello sold 5,000 shares of the stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $216.57, for a total value of $1,082,850.00. Following the completion of the sale, the chief financial officer now directly owns 38,204 shares in the company, valued…